DRMA vs. TSBX, EDSA, PBM, BFRI, AYTU, CYCN, CELZ, AIM, DWTX, and INDP
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Turnstone Biologics (TSBX), Edesa Biotech (EDSA), Psyence Biomedical (PBM), Biofrontera (BFRI), Aytu BioPharma (AYTU), Cyclerion Therapeutics (CYCN), Creative Medical Technology (CELZ), AIM ImmunoTech (AIM), Dogwood Therapeutics (DWTX), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry.
Dermata Therapeutics vs.
Dermata Therapeutics (NASDAQ:DRMA) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
Dermata Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.
Dermata Therapeutics has higher earnings, but lower revenue than Turnstone Biologics. Turnstone Biologics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Turnstone Biologics' return on equity of -105.99% beat Dermata Therapeutics' return on equity.
8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 9.4% of Dermata Therapeutics shares are held by insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Dermata Therapeutics received 1 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 50.00% of users gave Dermata Therapeutics an outperform vote while only 44.44% of users gave Turnstone Biologics an outperform vote.
Dermata Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 380.00%. Turnstone Biologics has a consensus target price of $0.45, suggesting a potential upside of 15.80%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dermata Therapeutics is more favorable than Turnstone Biologics.
In the previous week, Dermata Therapeutics' average media sentiment score of 0.00 equaled Turnstone Biologics'average media sentiment score.
Summary
Dermata Therapeutics and Turnstone Biologics tied by winning 7 of the 14 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dermata Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DRMA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free DRMA Stock Alerts